BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company dedicated to developing novel antibacterial products for serious infections caused by multi-drug resistant (MDR) bacteria, announced that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held from September 14-16, 2026, in New York City.
Chief Financial Officer Hernan Levett will present on September 16, 2026, from 12:30 to 1:00 PM ET in the Kennedy II room at the Lotte New York Palace. Additionally, a pre-recorded presentation by Chief Executive Officer Dr. Marc Gitzinger will be available on demand starting September 11, 2026, at 7:00 AM ET, with replays accessible for 90 days via the H.C. Wainwright platform or the BioVersys website.
The presentations come at a pivotal time for BioVersys, as the company advances its pipeline targeting some of the most challenging resistant bacteria. Its lead program, BV100, is in Phase 3 for nosocomial infections caused by Acinetobacter baumannii, a pathogen identified by the World Health Organization as a critical priority for new antibiotics. The company is also developing alpibectir for tuberculosis in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France. These programs leverage BioVersys' proprietary TRIC and Ansamycin Chemistry platforms, which aim to overcome resistance mechanisms and block virulence production.
The significance of this presentation lies in the urgent global need for new antimicrobial treatments. Antimicrobial resistance (AMR) is a growing crisis, with drug-resistant infections causing over a million deaths annually worldwide. BioVersys is among the few companies focusing on novel approaches to combat resistant bacteria, particularly in hospital settings where infections like those caused by A. baumannii can be fatal. The company's progress in Phase 3 and Phase 2 trials underscores the potential to bring new therapies to market, addressing a critical unmet medical need.
Investors and industry stakeholders will be keen to hear updates on BioVersys' clinical development plans, potential partnerships, and regulatory pathways during the conference. The availability of CEO and CFO for one-on-one meetings offers an opportunity for deeper engagement with the investment community.
BioVersys, headquartered in Basel, Switzerland, is recognized for its innovative research and development in the antimicrobial and microbiome fields. Its pipeline also targets bacteria-exacerbated chronic inflammatory disorders, expanding the potential impact of its technology beyond acute infections.
As AMR continues to challenge global health systems, BioVersys' presentations at this major investment conference highlight the company's role in advancing solutions. The event provides a platform to showcase its scientific progress and strategic vision, which could influence future investment and collaborative opportunities.
